What does Krystal biotech do?

Krystal Biotech is focused on the underlying genetic causes of these conditions and developing targeted therapies to provide long-term benefits for patients by pioneering the development of redosable gene therapies targeting diseases and tissues underserved by other approaches.

How did Krystal biotech perform in 2023?

The company's financial achievements in 2023 include a net product revenue of $42.1 million in the fourth quarter and $50.7 million for the full year. This performance is particularly noteworthy for a biotechnology company like Krystal Biotech, where product revenue is critical for sustaining research and development efforts.

What time is Krystal biotech market open?

As of 10:30 AM EDT. Market Open. Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).